Page contentsKey factsDecisionRelated contentTopicsKey facts Invented name Tobi PodhalerTobi Podhaler Active Substance Tobramycin Therapeutic area Infectious diseases Decision number P/0114/2017 PIP number EMEA-000184-PIP03-16 Pharmaceutical form(s) Inhalation powderCapsule (hard) Condition(s) / indication(s) Treatment of Pseudomonas aeruginosa pulmonary colonisation in patients with bronchiectasis Route(s) of administration Inhalation use Contact for public enquiries Mylan IRE Healthcare LimitedE-mail: info.uk@viatris.comTel. + 44 (0)1707853000 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 11/04/2017DecisionP/0114/2017: EMA decision of 11 April 2017 on the granting of a product specific waiver for tobramycin (TOBI Podhaler) (EMEA-000184-PIP03-16)AdoptedReference Number: EMA/199884/2017 English (EN) (69.93 KB - PDF)First published: 29/05/2017Last updated: 29/05/2017ViewRelated contentTobi PodhalerTopicsPaediatricsShare this page